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A B S T R A C T
We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) avail-
ability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease
stages, and 12 healthy controls. All participants received one [11C]raclopride PET scan in an OFF medication
condition for quantiﬁcation of striatal D2R availability in vivo. Parametric images of [11C]raclopride non-dis-
placeable binding potential were generated from the dynamic [11C]raclopride scans using implementation of the
simpliﬁed reference tissue model with cerebellum as the reference tissue. PET data were interrogated for cor-
relations with clinical data related to disease burden and dopaminergic treatment. PD patients showed a mean
16.7% decrease in caudate D2R and a mean 3.5% increase in putaminal D2R availability compared to healthy
controls. Lower caudate [11C]raclopride BPND correlated with longer PD duration. PD patients on dopamine
agonist treatment had 9.2% reduced D2R availability in the caudate and 12.8% in the putamen compared to PD
patients who never received treatment with dopamine agonists. Higher amounts of lifetime dopamine agonist
therapy correlated with reduced D2Rs availability in both caudate and putamen. No associations between striatal
D2R availability and levodopa treatment and dyskinesias were found. In advancing PD the caudate and putamen
D2R availability are diﬀerentially aﬀected. Chronic exposure to treatment with dopamine agonists, but no le-
vodopa, suppresses striatal D2R availability, which may have relevance to output signaling to frontal lobes and
the occurrence of executive deﬁcits, but not dyskinesias.
1. Introduction
Postsynaptic striatal dopamine type-2 receptors (D2Rs) modulate
the striatopallidal and the striatocortical signaling pathways in the
basal ganglia output nuclei. In Parkinson's disease (PD), stimulation of
these pathways is aﬀected due to the progressive degeneration of do-
paminergic neurons (Samii et al., 2004; Herz et al., 2015), leading to
alterations in synaptic dopamine levels and the development of motor
symptoms (Pavese et al., 2006), cognitive symptoms (Sawamoto et al.,
2008a, 2008b), and dyskinesias (Politis et al., 2014). Although long-
term changes in D2R availability may be also implicated (Antonini
et al., 1997), it is unclear how these changes are aﬀected by the pro-
gression of the disease and the dopaminergic treatment in patients with
PD.
[11C]raclopride PET is a selective marker and a valuable tool for
investigating D2R availability in vivo (Laruelle, 2000). [11C]raclopride
PET studies in de novo PD patients have reported an increase in D2R
availability in the putamen contralateral to the more aﬀected limbs,
while the D2R availability in the caudate remains intact (Rinne et al.,
1993; Turjanski et al., 1997). A combined PET study with [18F]ﬂuoro-L-
dopa (F-DOPA), a marker of pre-synaptic dopamine storage capacity,
and [11C]raclopride reported inverse correlations between reduced F-
DOPA and increased post-synaptic D2R in de novo PD (Sawle et al.,
1993). Therefore, in early denovo PD, upregulation of post-synaptic D2R
in the putamen could be a compensatory mechanism in response to
depletion of pre-synaptic dopaminergic terminals and synaptic dopa-
mine levels. However, as PD progresses D2R availability normalizes in
the putamen, but availability in the caudate is reduced (Antonini et al.,
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1997; Turjanski et al., 1997; Brooks et al., 1992; Dentresangle et al.,
1999). As the disease progresses and increasing degeneration of ni-
grostriatal dopamine neurons occurs this compensatory mechanism
fails; leading to decreased D2R availability in caudate. Furthermore,
after 3–5 years of levodopa treatment, [11C]raclopride binding is sig-
niﬁcant reduced in the putamen and caudate compared to baseline
(Antonini et al., 1997). These ﬁndings suggest that down-regulation of
striatal D2R in PD may be induced by chronic dopaminergic treatment.
Alterations in D2R function have been also suggested to play a role in
mechanisms underlying dyskinesias in PD (Boyce et al., 1990; Graham
et al., 1993).
Here we used [11C]raclopride PET to explore the integrity of striatal
D2R ligand binding and its relevance to the development of clinical
symptoms and the chronic exposure to dopaminergic treatment in a
group of patients with PD.
2. Materials and methods
2.1. Participants
We studied 68 patients with idiopathic PD according to the UK Brain
Bank clinical diagnostic criteria. All PD patients were receiving dopa-
mine replacement therapy. To assess the eﬀect of dopamine agonist
treatment, PD patients were divided into two groups, those who were
receiving dopamine agonists (n = 46; either Ropinerole or
Pramipexole, not in extended release) and patients who had never re-
ceived treatment with dopamine agonists (n = 22). Apart from levo-
dopa and dopamine agonists, PD patients were not on any other med-
ication with known action on dopamine receptors. Twelve healthy
individuals matched for age and gender, with no history of neurological
or psychiatric illness served as the healthy control group. All subjects
were non-demented (Table 1).
2.2. Clinical assessments
PD subjects were staged for disease severity with the Hoehn and
Yahr (H & Y) scale and were clinically assessed with the Uniﬁed
Parkinson's Disease Rating Scale (UPDRS), Abnormal Involuntary
Movement Scale (AIMS), Mini-Mental State Examination (MMSE) and
Beck Depression Inventory (BDI-II). Daily and lifetime dopamine ago-
nist equivalent dose (LEDDA) and daily and lifetime levodopa equivalent
dose (LEDL-DOPA) unit calculations were based on theoretical
equivalence to levodopa as described previously (Politis et al., 2014;
Politis et al., 2010).
2.3. Scanning procedures
All subjects had [11C]raclopride PET and 1.5-Tesla (T) volumetric
MRI in an OFF medication condition after 18 h withdrawal of dopa-
minergic medications. Long acting dopaminergic medications were
withdrawn for 72 h prior to the PET scan. PET imaging was performed
at the Cyclotron Unit (Hammersmith Hospital) and [11C]raclopride
radiotracer was supplied by Hammersmith Imanet plc, London, UK. All
subjects were scanned using an ECAT HR+ (CTI/Siemens 962) 3D PET
tomography scanner, with 15.5 cm total axial ﬁeld of view (FOV). This
camera has a mean image transaxial resolution (3D mode) over a 10 cm
radius FOV of 6.0 + 0.5 mm and an axial resolution of 5.0 + 0.8 mm
(Brix et al., 1997). All subjects were scanned following administration
of [11C]raclopride as an intravenous bolus, mean dose 250 MBq; PET
images were obtained as 20 time frames acquired over 60 min. Volu-
metric T1-weighted MRI scans were acquired using a 1.5 T MRI (Picker
Eclipse, Picker International Inc., Highlands Heights, OH, USA). MRI
was performed on the same day as the PET for co-registration of
functional images.
The study received ethical approval from the Ethics Committee of
Hammersmith, Queen Charlotte's and Chelsea and Acton Hospitals. All
subjects gave informed written consent in accordance with the
Declaration of Helsinki.
2.4. [11C]raclopride PET image analysis
2.4.1. Movement correction
Head movement correction was carried out for all PET images using
frame-by-frame realignment (Montgomery et al., 2006) with in-house
software (c-wave) implemented in Matlab 8.2 (The MathWorks Inc.).
Non-attenuated corrected images were denoised using a level 2, order
64 Battle Lemarie wavelet ﬁlter (Turkheimer et al., 1999) followed by
realignment using a mutual information algorithm (Studholme et al.,
1997). The ﬁrst three frames were excluded and frame 10 was chosen as
the reference frame due to good signal-to-noise ratio. Frames 4–20 of
the original time series were resliced and reassembled into a movement-
corrected dynamic scan. Decay-corrected time-activity curves were
derived and compared to those without movement correction. The
amount and timing of any movements were assessed graphically and
Table 1
Clinical characteristics of Parkinson's disease patients and healthy controls.
Parkinson's disease patients Healthy controls
No of subjects 68 12
Sex 52 M/16F 10 M/2F
Age (years ± SD) 62.8 (± 9.1) 63.3 (± 7.0)
Disease duration (years ± SD)a 10.71 (± 6.4) –
H&Y OFF (mean ± SD) 2.8 (± 0.94) –
UPDRS Part-III OFF (mean ± SD) 42.0 (± 13.0) –
UPDRS Part-III ON (mean ± SD) 20.8 (± 8.9) –
MMSE (mean ± SD) 29.2 (± 1.4) 29.4 (± 0.7)
BDI-II (mean ± SD) 13.7 (± 8.7) 3.1 (± 2.6)
Duration of dopaminergic therapy (years ± SD) 6.5 (± 4.1) –
Duration of dopamine agonist (DA) treatment (years ± SD) 4.3 (± 3.7) –
Duration of levodopa (L-DOPA) treatment (years ± SD) 5.5 (± 4.2) –
Daily LEDL-DOPA (mg ± SD) 739.0 (± 31.9) –
Daily LEDDA (mg ± SD) 173.8 (± 180.4) –
Daily LEDTOTAL (mg ± SD) 911.0 (± 721.6) –
Lifetime LEDL-DOPA (g ± SD) 991.5 (± 057.6) –
Lifetime LEDDA (g ± SD) 299.4 (± 391.4) –
Lifetime LEDTOTAL (g ± SD) 1291.0 (± 1250.8) –
a Disease duration has been accounted from time of ﬁrst appearance of PD symptoms; LEDL-DOPA = levodopa equivalent dose; LEDDA = dopamine agonists equivalent
dose; H & Y = Hoehn and Yahr; MMSE =Mini Mental State Examination; BDI-II = Beck Depression inventory; HRSD = Hamilton Rating Scale for Depression.
SD = Standard Deviation.
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compared with intrascan notes. Motion correction was applied to all
PET data, however since patients were scanned oﬀ medication, the ef-
fect of head movement has to be considered when interpreting the
ﬁndings.
2.4.2. Parametric images
Parametric [11C]raclopride non-displaceable binding potential
(BPND) images were generated from the dynamic [11C]raclopride scans
using a basis function implementation of the simpliﬁed reference tissue
model, with the cerebellum as the reference region for non-speciﬁc
binding (Gunn et al., 1997). PET images were coregistered and resliced
to corresponding volumetric T1-weighted MR images using the Mutual
Information Registration algorithm in the Statistical Parametric Map-
ping (SPM, version 8) software package (Wellcome Department of
Cognitive Neuroscience, Institute of Neurology, London, UK) im-
plemented in Matlab 8.2.
2.4.3. Region of interest analysis
Regions-of-interests (ROIs) were manually delineated on individual
co-registered volumetric T1-weigthed MRI images and sampled on
parametric PET images, using ANALYZE medical imaging software
(Mayo Foundation, Rochester, MN, USA, Version 10). A reliable, robust
and repeatable technique was used for manual delineation of ROIs
using the Talairach and Tournoux (Talairach and Tournous, 1988)
stereotaxic atlas in combination with Duvernoy 3-dimensional sectional
atlas (Duvernoy, 1999) on individual coregistered MRIs. The anterior
border for the cerebellum was deﬁned by the inferior semilunar lobule,
the posterior border and the lateral border was deﬁned by the trans-
verse sinus and the medial border by the cerebellar falx. The anterior
border for the caudate nucleus was deﬁned by the lateral ventricle, the
posterior border by the internal capsule, the medial border by the lat-
eral ventricle and fornix, and the lateral border was deﬁned by the
external capsule. The anterior border for the putamen was deﬁned by
the anterior limb of the internal capsule, the posterior border by the
posterior limb of the internal capsule, the lateral border by the external
capsule/claustrum, and the medial border by the lamina medullaris
lateralis. For each subject ROIs were manually delineated in both
hemispheres. To minimize possible partial volume eﬀects, anatomical
data from high resolution MRI was used to manually delineate speciﬁc
ROIs ensuring the volume for each ROI was standardized so there was
no signiﬁcant diﬀerence in ROI volume across groups. Therefore, re-
ducing the eﬀects of partial volume diﬀerence between groups which
could account for changes in binding potential.
2.5. MRI volumetric analysis
FreeSurfer's image analysis suite (version 6) was used to process
individual MRI scans to derive measures of subcortical volumes using
automated procedures previous described (Fischl et al., 2002). Sub-
cortical volumes were normalized for intracranial volume using vali-
dated methods within the FreeSufer toolkit (Buckner et al., 2004).
2.6. Statistics
Statistical analysis and graph illustrations were performed with
SPSS (version 22) and GraphPad Prism (version 6.0) for MAC OS X,
respectively. For all variables, variance homogeneity and Gaussianity
were tested with Bartlett and Kolmogorov-Smirnov tests. Repeated-
measures analysis of covariance was used to interrogate the association
between medication condition and clinical characteristics with D2
binding where and [11C]raclopride BPND in ROIs was the repeated
measure. If a signiﬁcant interaction was found between a medication
and clinical variable and the repeated-measure variable ROI, univariate
tests were then carried out on the individual ROIs and resulting p values
were corrected for multiple comparisons.
We compared [11C]raclopride BPND in the caudate and putamen
between PD patients and healthy controls. We assessed the eﬀect of
medication on caudate and putamen [11C]raclopride BPND in PD pa-
tients receiving dopamine agonists (n = 46) compared to PD patients
not receiving dopamine agonists (n = 22). To assess the eﬀect of dys-
kinesias on the integrity of striatal D2Rs, PD subjects were categorized
into two groups depending on having dyskinesias (n = 38) or not
having dyskinesias (n = 30).
[11C]raclopride BPND in the caudate and putamen were checked for
associations with (a) disease duration, (b) UPDRS Part-III motor scores
in ON and OFF medication state, (c) AIMS scores (d) BDI-II scores, (e)
dopamine agonist and levodopa treatment duration and (f) amount of
daily and lifetime dopamine agonist and levodopa intake. Possible
correlations between PET and clinical data were carried out using
Pearson r and Spearman ρ depending on the distribution of each vari-
able; the analyses were repeated including age as covariate. Hochberg-
multiple comparison correction was applied for each set of correlations
using PPLot (version 1.0) in Matlab (Turkheimer et al., 2001). All data
are presented as mean ± SD and the level of α was set for all com-
parisons at p < 0.05, corrected.
3. Results
PD patients had a mean disease duration of 10.7 years and mean
6.5 years of dopaminergic drug treatment (Table 1). PD patients
(n = 68) showed a mean 16.7% decrease in caudate [11C]raclopride
BPND compared to healthy controls (p < 0.001). In the putamen PD
patients showed a mean 3.5% increase in [11C]raclopride BPND com-
pared to healthy controls (Table 2). Lower individual caudate [11C]
raclopride BPND values correlated with longer disease duration
(Pearson r=−0.39, p = 0.0012; Fig. 1). No correlations were found
between [11C]raclopride BPND and UPDRS or BDI-II scores.
3.1. Volumetric analysis
FreeSurfer analysis revealed no volumetric diﬀerence in the left and
right caudate and putamen between PD patients and healthy controls
(p > 0.10).
Table 2
Caudate and putamen [11C]raclopride binding potentials in healthy controls and Parkinson's disease patients.
Caudate [11C]raclopride BPND Putamen [11C]raclopride BPND
Healthy controls (n = 12; mean ± SD) 2.27 (± 0.2) 2.58 (± 0.2)
All PD patients (n = 68; mean ± SD; Δ%) 1.89 (± 0.3)⁎⁎⁎; −16.7% 2.67 (± 0.5); +3.5%
Non-dyskinetic PD patients (n = 30; mean ± SD; Δ%) 2.03 (± 0.3)⁎; −10.6% 2.76 (± 0.4); +7.0%
Dyskinetic PD (n = 38; mean ± SD; Δ%) 1.78 (± 0.4)⁎⁎⁎; −21.6% 2.59 (± 0.5); +0.4%
PD patients receiving NO dopamine agonist treatment (n = 22; mean ± SD; Δ%) 2.03 (± 0.3)⁎; −10.6% 2.89 (± 0.4)*; +12.0%
PD patients receiving dopamine agonist treatment (n = 46; mean ± SD; Δ%) 1.82 (± 0.3)⁎⁎⁎; −19.8% 2.56 (± 0.5); −0.8%
Δ%= percentage diﬀerence compared to healthy controls; BPND = non-displaceable binding potential; PD = Parkinson's disease.
⁎ p < 0.05.
⁎⁎⁎ p < 0.001.
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3.2. Eﬀect of medication on D2R availability
PD patients on dopamine agonist treatment had no diﬀerences in
terms of age, cognitive status (MMSE), depression levels (BDI-II), dis-
ease stage and burden compared to PD patients who had not received
treatment with dopamine agonists (p > 0.05). We found a signiﬁcant
interaction between dopamine agonist treatment and [11C]raclopride
BPND in ROIs (p < 0.001).
Compared to healthy controls, PD patients who had not received
treatment with dopamine agonists (n = 22) showed a mean 10.6%
decreased caudate [11C]raclopride BPND (p < 0.05) and a mean 12%
increased putamen [11C]raclopride BPND (p < 0.05) (Table 2; Fig. 2A).
PD patients on dopamine agonist treatment (n = 46) showed a mean
19.8% decrease in caudate [11C]raclopride BPND (p < 0.001) and a
mean 0.8% decrease in putamen [11C]raclopride BPND compared to
healthy controls (Table 2; Fig. 2A). In comparisons to PD patients who
never received treatment with dopamine agonists, PD patients on do-
pamine agonist treatment had 9.2% reduced D2R availability in the
caudate (p < 0.05) and 12.8% decreased in the putamen (p < 0.05)
(Fig. 2A). There were no diﬀerences in the relation between BPND and
speciﬁc dopamine agonists (ropinerole or pramiprexole).
Higher amounts of lifetime dopamine agonist therapy correlated
with lower individual [11C]raclopride BPND values in the caudate
(Spearman ρ=−0.33; p < 0.05) and in the putamen (Spearman
ρ=−0.33; p < 0.05) of PD patients. These results remained sig-
niﬁcant after using age as a covariate (caudate ρ=−0.32, p < 0.05;
putamen ρ= 0.31, p < 0.05). Levodopa treatment duration, levodopa
daily and lifetime amount were not associated with [11C]raclopride
BPND values in the caudate and in the putamen.
3.3. Eﬀect of dyskinesias on D2R availability
We found a signiﬁcant interaction between the presence of dyski-
nesias and [11C]raclopride BPND in ROIs (p < 0.001). PD patients with
dyskinesias (n = 38) showed a mean 21.6% decreased caudate [11C]
raclopride BPND (p < 0.001) and a mean 0.4% increased [11C]raclo-
pride BPND in the putamen compared to healthy controls (Fig. 2B). PD
patients without dyskinesias (n = 30) showed a mean 10.6% decreased
caudate [11C]raclopride BPND (p < 0.05) and a mean 7% increased
[11C]raclopride BPND in the putamen compared to healthy controls
(Table 2; Fig. 2B).
PD patients with dyskinesias had longer disease duration
(p < 0.001), were at a more advanced disease stage (H & Y OFF:
p < 0.001), and had received larger amounts of dopaminergic therapy
(LEDtotal: p < 0.001) due to higher levodopa doses (Daily LEDL-DOPA:
p < 0.001) compared to PD patients with no dyskinesias. Dopamine
agonist intake was no diﬀerent between PD patients with and without
dyskinesias (LEDDA: p > 0.10). We found no correlations between in-
dividual caudate or putamen [11C]raclopride BPND values and AIMS
scores. These results were conﬁrmed after controlling for age.
4. Discussion
Our [11C]raclopride PET ﬁndings demonstrate that as PD advances
striatal D2R availability is altered and is inﬂuenced by chronic exposure
to dopamine agonist treatment. We found a mean 16.7% loss of D2R
availability in the caudate and a mean 3.5% increase of D2R availability
in the putamen in the collective cohort of PD patients studied. In PD
patients who had never received treatment with dopamine agonists,
D2R availability in the caudate was reduced by 10.8% and in the pu-
tamen was increased by 12%. In contrast, matched PD patients on do-
pamine agonist treatment had 9.2% reduced D2R availability in the
caudate and 12.8% reduction in the putamen compared to PD patients
who had not received treatment with dopamine agonists. Higher
amounts of dopamine agonist therapy received over PD patient's life-
time correlated with reduced D2R availability in both caudate and
putamen.
Post mortem studies have reported normal (Pierot et al., 1988), re-
duced (Rinne et al., 1991) or increased (Bokobza et al., 1984) D2R
binding in the striatum of PD patients treated with dopaminergic drugs.
Previous [11C]raclopride PET studies have suggested that reductions in
caudate D2R availability in advanced PD stages may reﬂect either dis-
ease progression or an eﬀect of chronic exposure to dopaminergic
therapy (Antonini et al., 1994; Turjanski et al., 1997; Brooks et al.,
1992; Dentresangle et al., 1999). Our [11C]raclopride PET ﬁndings
suggest that with longer disease duration, D2R availability is reduced in
the caudate, but not in the putamen. Chronic exposure to dopamine
agonist treatment suppresses D2R availability in both the caudate and
Fig. 1. Correlation between Parkinson disease duration and caudate postsynaptic dopa-
mine receptor type-2 availability. Inverse correlation between individual caudate [11C]
raclopride BPND values and disease duration in Parkinson's disease patients (n = 68).
Fig. 2. Eﬀect of dopamine agonist treatment (A)
and presence of dyskinesia (B) on dopamine re-
ceptor type-2 receptor availability in the caudate
and putamen of patients with Parkinson's disease.
*p < 0.05; **p < 0.001.
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putamen. Dopamine agonists directly target D2Rs mimicking the eﬀects
of endogenous dopamine. Therefore, down-regulation could be the re-
sult of direct competition between [11C]raclopride and exogenous
sources of dopamine, or due to internalization of D2R upon dopamine
binding leading to reduced availability of [11C]raclopride binding sites.
According to our ﬁndings chronic treatment with levodopa does not
inﬂuence striatal D2R availability in PD. It has been shown that chronic
exposure to levodopa mainly aﬀects striatal D1R availability (Turjanski
et al., 1997).
Previous [11C]raclopride PET studies in de novo PD patients have
shown up to 20% increases in D2R availability in the putamen while the
D2R availability in the caudate was normal (Turjanski et al., 1997;
Leenders and Antonini, 1992; Antonini et al., 1994). Further [11C]ra-
clopride PET studies have shown that as PD progresses, D2R availability
normalizes in the putamen, but D2Rs in the caudate are reduced by
around 20% (Turjanski et al., 1997; Brooks et al., 1990; Brooks et al.,
1992; Dentresangle et al., 1999; Antonini et al., 1994). Our [11C]ra-
clopride PET ﬁndings are compatible with the previous [11C]raclopride
PET studies, showing that D2R availability in the striatum is aﬀected by
advancing disease stage and suppressed by chronic exposure to dopa-
mine agonist treatment. Dopamine agonist intake may also explain the
normalization of putaminal [11C]raclopride availability and further
reductions of caudate [11C]raclopride availability in advanced PD that
has been reported in the previous studies (Turjanski et al., 1997; Brooks
et al., 1990; Brooks et al., 1992; Dentresangle et al., 1999; Antonini
et al., 1994). Dopamine agonists exert their pharmacological eﬀect by
directly activating post-synaptic D2Rs. Putaminal D2R availability re-
turns to within normal levels in PD patients receiving dopamine agonist
treatment, counteracting compensatory D2R up-regulation observed in
the putamen in the absence of dopaminergic treatment. Therefore, early
treatment with dopamine agonists could have beneﬁcial eﬀects to slow
loss of dopamine terminal function in the putamen. Moreover, another
[11C]raclopride PET study has shown that withdrawal of dopaminergic
drugs in previously treated advanced PD patients, undergoing deep
brain stimulation of the subthalamic nucleus, resulted in up-regulation
of striatal D2Rs (Thobois et al., 2004). The authors of this study did not
investigate the eﬀect of dopaminergic treatment but our ﬁndings sug-
gest this would have been due to withdrawal of dopamine agonist
treatment. Fig. 3 illustrates the summary of our ﬁndings taken together
with the ﬁndings from the previous [11C]raclopride PET studies re-
garding striatal D2R availability in advanced PD patients treated with
and without dopamine agonists.
Our ﬁndings show that longer PD duration correlated with de-
creased D2R availability in the caudate but not in the putamen. These
ﬁndings suggest that although caudate and putamen D2R availability is
aﬀected with advancing disease, the loss of D2R availability is linear in
the caudate and non-linear or linear with a wide variance in the pu-
tamen (Fig. 3). A future longitudinal study, with stratiﬁed treatment
arms, is required to conﬁrm the true kinetics of putamen D2R reduc-
tions. The gradual loss of D2R availability in the caudate could impact
the output signaling pathways from the caudate to the frontal cortex,
which are critical for executive functions. A previous [11C]raclopride
PET study has shown that signiﬁcant attenuation of dopamine release in
the caudate was associated with executive deﬁcits in patients with PD
(Sawamoto et al., 2008a, 2008b). Similar associations between loss of
caudate D2R availability and cognitive dysfunction have also been re-
ported in Huntington's disease (Pagano et al., 2016). Therefore, reduced
D2R availability in the caudate, likely worsened with dopamine agonist
treatment, could have implications for cognitive impairments and ex-
ecutive function deﬁcits in PD patients. Further longitudinal studies, in
larger cohorts of PD patients, are required to fully understand the im-
pact of dopamine agonist treatment, and altered D2R availability, on
cognitive symptomatology in advancing PD.
Our [11C]raclopride ﬁndings also show that PD patients with dys-
kinesias had greater striatal reductions (11% in the caudate and 6.6% in
the putamen) in D2R availability compared to PD patients without
dyskinesias. PD patients with dyskinesias, however, were more disabled
and had more advanced disease. Also, we found no correlations be-
tween striatal D2R availability and dyskinesias scores and therefore, our
ﬁndings suggest that the diﬀerence in striatal D2R availability between
dyskinetic and non-dyskinetic PD reﬂects the more advanced disease in
the dyskinetic PD group rather than a direct relationship between the
development of dyskinesias and D2R availability. These ﬁndings are
compatible with a previous [11C]raclopride PET study which demon-
strated no association between striatal D2R availability and dyskinesias
in PD (Turjanski et al., 1997). Although it has been postulated that
alterations in striatal D2Rs may be involved in the development of
dyskinesias in PD (Boyce et al., 1990; Graham et al., 1993), it is more
likely that loss of dopamine terminals and priming with levodopa play a
prominent role. Other non-dopaminergic systems such as the gluta-
matergic and the serotonergic may play a prominent role in the de-
velopment of dyskinesias in PD (Niccolini et al., 2015; Politis et al.,
2014). Lines of evidence suggest that relatively preserved presynaptic
serotonergic terminals in the basal ganglia mishandle synaptic levels of
dopamine and contribute in the occurrence of dyskinesias in PD (Politis
et al., 2014; Smith et al., 2015).
In conclusion, our ﬁndings indicate that D2R availability in the
caudate and in the putamen are diﬀerentially aﬀected with advancing
PD. Chronic exposure to treatment with dopamine agonists, but not
levodopa, suppresses striatal D2R availability, which may have re-
levance to caudate output signaling to frontal lobes and the occurrence
of executive deﬁcits, but not dyskinesias. Availability of D2Rs is not
conﬁned only to the striatum and previous PET studies have shown
alterations in extra-striatal regions that may be implicated in the de-
velopment of non-motor symptoms in PD (Kaasinen et al., 2000;
Kaasinen et al., 2003; Politis et al., 2008). Hopefully, future studies will
help understand the relevance of extra-striatal D2R system in the de-
velopment of non-motor symptoms and the associations with exposure
to dopaminergic treatment in patients with PD.
Fig. 3. Graphical representation of caudate and putamen dopamine receptors type-2
(D2R) availability in patients with Parkinson's disease. The illustration summarizes our
ﬁndings together with the ﬁndings from the previous [11C]raclopride PET studies (Brooks
et al., 1990; Brooks et al., 1992; Leenders and Antonini, 1992; Rinne et al., 1993; Antonini
et al., 1994; Antonini et al., 1997; Turjanski et al., 1997; Dentresangle et al., 1999) and
shows a linear caudate reduction and a non-linear reduction of D2R availability in the
putamen as PD progresses. Also, the suppressing eﬀect of chronic dopamine agonist
treatment in striatal D2R availability in patients with PD. PD = Parkinson's disease;
D2R = dopamine receptor type-2.
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